Literature DB >> 15187784

Is an abbreviated Pediatric Crohn's Disease Activity Index better than the original?

Melissa A Shepanski1, Jonathan E Markowitz, Petar Mamula, Linda B Hurd, Robert N Baldassano.   

Abstract

OBJECTIVE: The Pediatric Crohn's Disease Activity Index (PCDAI) is a validated measure of disease activity comprised of historical, laboratory and physical examination parameters. It has been suggested that an abbreviated PCDAI may be of similar utility without requiring laboratory evaluations or calculated height velocity. The aim of this study was to compare an abbreviated PCDAI and the original PCDAI and also compare the abbreviated PCDAI and a quality-of-life measurement.
METHODS: The authors prospectively analyzed quality of life and disease activity, using the IMPACT-35 Questionnaire, the PCDAI and an abbreviated PCDAI consisting of three historical items (abdominal pain, stools and patient functioning) and three physical examination items (weight, abdomen and perirectal disease).
RESULTS: Forty subjects aged 5-24 years (22 males) were included in analysis. Correlations were performed between the original PCDAI, an abbreviated PCDAI and the IMPACT-35. There was a significant, strong correlation between the PCDAI and the abbreviated PCDAI (n = 40, r = 0.849, p <0.001), a significant, moderate correlation between PCDAI and IMPACT-35 (n = 29, r = -0.547, p = 0.002) and a significant, moderate correlation between the abbreviated PCDAI and IMPACT-35 (n = 29, r = -0.579, p <0.001).
CONCLUSIONS: An abbreviated PCDAI predicted disease activity as well as the full PCDAI. The IMPACT-35 correlated well with disease activity based on both PCDAI and an abbreviated PCDAI. An abbreviated PCDAI may offer advantages over the original PCDAI and should be prospectively validated in future studies.

Entities:  

Mesh:

Year:  2004        PMID: 15187784     DOI: 10.1097/00005176-200407000-00014

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  20 in total

1.  Severe myalgia associated with mesalazine treatment in a child with Crohn's disease.

Authors:  Mladen Persić; Goran Palcevski; Irena Slavić; Vera Vlahović-Palcevski
Journal:  Eur J Clin Pharmacol       Date:  2007-01-23       Impact factor: 2.953

2.  Preparing adolescents with chronic disease for transition to adult care: a technology program.

Authors:  Jeannie S Huang; Laura Terrones; Trevor Tompane; Lindsay Dillon; Mark Pian; Michael Gottschalk; Gregory J Norman; L Kay Bartholomew
Journal:  Pediatrics       Date:  2014-05-19       Impact factor: 7.124

3.  Stability of Emotional and Behavioral Functioning in Youth with Inflammatory Bowel Disease.

Authors:  Bonney Reed-Knight; Debra Lobato; Sarah Hagin; Elizabeth L McQuaid; Ronald Seifer; Sheryl J Kopel; Julie Boergers; Jack H Nassau; Kristina Suorsa; Barbara Bancroft; Neal S LeLeiko
Journal:  Child Health Care       Date:  2013-10-22

4.  Short pediatric Crohn's disease activity index for quality improvement and observational research.

Authors:  Michael D Kappelman; Wallace V Crandall; Richard B Colletti; Anthony Goudie; Ian H Leibowitz; Lynn Duffy; David E Milov; Sandra C Kim; Bess T Schoen; Ashish S Patel; John Grunow; Evette Larry; Gerry Fairbrother; Peter Margolis
Journal:  Inflamm Bowel Dis       Date:  2010-09-01       Impact factor: 5.325

5.  Clinical and Phenotypic Differences in Inflammatory Bowel Disease Among Arab and Jewish Children in Israel.

Authors:  Firas Rinawi; Amit Assa; Husam Bashir; Sarit Peleg; Raanan Shamir
Journal:  Dig Dis Sci       Date:  2017-05-25       Impact factor: 3.199

6.  Rates and predictors of oral medication adherence in pediatric patients with IBD.

Authors:  Neal S LeLeiko; Debra Lobato; Sarah Hagin; Elizabeth McQuaid; Ronald Seifer; Sheryl J Kopel; Julie Boergers; Jack Nassau; Kristina Suorsa; Jason Shapiro; Barbara Bancroft
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

7.  Depressive symptoms in youth with inflammatory bowel disease compared with a community sample.

Authors:  Bonney Reed-Knight; Debra Lobato; Sarah Hagin; Elizabeth L McQuaid; Ronald Seifer; Sheryl J Kopel; Julie Boergers; Jack H Nassau; Kristina Suorsa; Barbara Bancroft; Jason Shapiro; Neal S Leleiko
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325

8.  Serum Interleukin-33 level in Saudi children with inflammatory bowel disease.

Authors:  Omar I Saadah; Sameer E Al-Harthi; Jamil A Al-Mughales; Yagoub Y Bin-Taleb; Raed S Baeshen
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

9.  Use of Reticulocyte Hemoglobin Content in the Assessment of Iron Deficiency in Children With Inflammatory Bowel Disease.

Authors:  Sana Syed; Subra Kugathasan; Archana Kumar; Jarod Prince; Bess T Schoen; Courtney McCracken; Thomas R Ziegler; Parminder S Suchdev
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-05       Impact factor: 2.839

10.  Retinol Binding Protein 4 in children with Inflammatory Bowel Disease: a negative correlation with the disease activity.

Authors:  E Roma; M Krini; E Hantzi; S Sakka; I Panayiotou; A Margeli; I Papassotiriou; C Kanaka-Gantenbein
Journal:  Hippokratia       Date:  2012-10       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.